Your Age Is Not Your Medical History: What Changing Breast Cancer Care Can Teach Us

A date of birth is useful information. It is not a medical history. Two people of the same age can have different tumour biology, health conditions, day-to-day capacity, family responsibilities and views about treatment. Good cancer care has to take account of more than the number of birthdays someone has had.

That does not mean age is irrelevant, or that personalised care can guarantee a better outcome. Age can be one part of a clinical picture, and some treatments carry risks that depend on a person’s overall health. The point is narrower: an age label by itself does not explain what a particular breast cancer is, what a person can tolerate, or which trade-offs matter to them.

Start with the tumour—not a headline about age

Breast cancer is not one uniform disease. Clinicians use information about the tumour, such as its size, grade, spread and receptor status, to classify it and discuss possible care. Two markers that often appear in reports are hormone receptors (HR) and human epidermal growth factor receptor 2 (HER2).

Hormone-receptor testing looks for receptors such as oestrogen receptor (ER) and progesterone receptor (PR). HER2 testing looks at a protein that can be present at higher levels in some breast cancers. These results help the clinical team understand features of the tumour and which types of treatment may be relevant to discuss. They are not a complete description of a person, and they do not by themselves determine the right plan.

Other details matter too. The stage of the cancer, whether it has spread, previous treatment, the person’s health and the likely benefits and burdens of an option all contribute. NICE guidance for early and locally advanced breast cancer includes recommendations about assessing tumour profiles, planning treatment and taking individual preferences into account.

Tumour biology can change over time

A tumour sampled at an initial diagnosis may not always have the same receptor pattern as cancer found later. NICE’s 2026 update to its breast-cancer quality standard says that HR and HER2 status should be assessed in newly diagnosed invasive breast cancer and, when clinically appropriate, in recurrent disease if a different result would change management.

This is one reason that a treatment headline cannot stand in for an individual discussion. Research may describe a group defined by one marker, at one stage of disease, after a particular previous treatment. A person’s own report and current clinical situation may differ. A test result also needs to be interpreted alongside the rest of the record.

“Personalised” does not mean that every patient receives every new test or the newest treatment. It means that a care discussion should be grounded in the information that is relevant to that person and the choices actually available to them. Testing itself can have limits, and sometimes a result will not change the options.

The person’s overall health matters as well

A clinician may need to understand how a treatment could interact with other conditions and medicines, affect daily function, or fit with what the person most wants to preserve. For some older adults considering systemic cancer treatment, professional guidance recommends a structured assessment of areas such as physical and cognitive function, other health conditions, falls, nutrition and emotional health. The purpose is not to deny treatment because of age; it is to identify support needs and make the plan more informed.

The American Society of Clinical Oncology (ASCO) guideline is a US professional guideline, not a description of what every NHS clinic offers. Its broader lesson is that ordinary oncology assessments may not capture every issue that matters to an older adult. In the UK, NICE’s breast-cancer recommendations and the NHS treatment guide describe care planning in the context of tumour type and general health. A person can ask their own team what assessments or support are appropriate in their situation.

This kind of careful discussion is relevant beyond older age. A person in their forties may have other health conditions, caring responsibilities or treatment preferences that need to be discussed. A fit person in their eighties may have a different set of priorities from someone of the same age. None of that can be inferred from a birthday alone.

A US development does not automatically mean NHS access

News about a promising trial, a US Food and Drug Administration (FDA) decision or a new treatment can understandably raise hope. Those are different things. A result from a trial is not the same as a regulator’s marketing authorisation. An FDA decision applies in the United States; it does not itself authorise a medicine for use in the UK or establish that the NHS will routinely provide it.

In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) is the medicines regulator. In England, NICE evaluates evidence and value and can recommend NHS use, sometimes through managed-access arrangements such as the Cancer Drugs Fund. The processes and access routes are not identical across every UK nation, and local clinical eligibility still matters. A headline from another country cannot answer whether a specific medicine is licensed, recommended or available through a person’s own NHS service.

For a current question, ask the breast-care team or specialist pharmacist about the exact treatment, the tumour features it is intended for, and the relevant pathway where you live. NICE’s explanation of accessing care and treatment recommended by NICE describes how recommendations relate to NHS access in England; check the current local guidance for your nation and circumstances.

Questions that can make an appointment clearer

You do not need to learn every oncology term before you can take part in a decision. It may help to bring a written list, ask someone you trust to come with you, or request that the team explain a result in plain language. Questions could include:

• “Which features of my tumour are most relevant to the options you are discussing?”
• “What do my ER, PR and HER2 results mean in my specific case?”
• “What is the likely benefit of each option, and what uncertainty remains?”
• “How might the options affect my day-to-day function, other conditions or medicines?”
• “Is the treatment available through the NHS where I live, and what would need to be true for me to be eligible?”
• “If I need time to think, who can I contact with another question?”

Shared decision making is not a test of how assertively someone speaks. NICE’s guidance encourages clinicians and people using services to work together, discuss risks and benefits, and consider what matters to the person. It is reasonable to ask for repetition, an interpreter, a written summary or another appointment if that would help you understand the choices.

Personalisation should make room for the person

Tests and treatment pathways are useful because they can organise complex evidence. They are not a substitute for listening. Someone may value more time at home, a particular form of independence, a future event, or the chance to understand every option before deciding. Another person may place the emphasis elsewhere. Those preferences do not determine the biology of a tumour, but they belong in a conversation about care.

If a diagnosis has made familiar assumptions about age feel suddenly inadequate, our reflection on what can change—and what can grow—with age considers the wider life around a health decision. It is not a cancer guide or a treatment recommendation. The clinical questions belong with the cancer team who knows the individual case.

The most useful conclusion is neither “age does not matter” nor “age decides.” A person’s date of birth is one fact among many. Tumour characteristics, overall health, available evidence, local access and personal priorities all help shape a discussion. The next step is not to match yourself to a headline, but to ask what the evidence means for the particular situation in front of you.

Sources / Further reading

• NICE: Early and locally advanced breast cancer—diagnosis and management (NG101).
• NICE: HR and HER2 receptor status, quality statement 4 (updated 2026).
• NHS: treatment for breast cancer.
• ASCO: practical assessment and management of vulnerabilities in older adults receiving systemic cancer therapy, guideline update (2023).
• NICE: shared decision making (NG197).
• MHRA: UK medicines and medical devices regulator.

This article is educational and does not recommend, select or rule out cancer treatment. It is not personal medical advice. Do not start, stop or change treatment based on this article or a news report; discuss decisions with the oncology team responsible for your care.